## Management of SJS/TEN: Evidence-Based Approach ### Critical First Step: Drug Withdrawal **Key Point:** Immediate discontinuation of the causative drug is the SINGLE most important intervention and is universally recommended. Continuation of the drug is associated with progression to TEN and increased mortality. **High-Yield:** The prognosis improves dramatically if the drug is stopped within the first 24–48 hours of symptom onset. ### Supportive Care: The Cornerstone **Clinical Pearl:** SJS/TEN are medical emergencies requiring ICU or specialized burn unit admission. Mortality is primarily due to: - Sepsis from loss of skin barrier - Fluid and electrolyte imbalance - Secondary infection - Multi-organ failure **Supportive measures include:** 1. Aggressive fluid resuscitation (using Parkland formula adapted for SJS/TEN) 2. Infection prevention (sterile handling, topical antimicrobials, prophylactic antibiotics) 3. Nutritional support (high-protein, high-calorie enteral feeding) 4. Pain management 5. Eye care (ophthalmology consultation for mucosal involvement) 6. Wound care (non-adherent dressings, avoid silver sulfadiazine) ### Systemic Corticosteroids: Controversial and NOT Universally Recommended **Warning:** The role of systemic corticosteroids in SJS/TEN is **highly controversial** and remains debated in the literature. #### Evidence Against Routine Corticosteroid Use: - **Meta-analyses and observational studies** show no clear mortality benefit - Some studies suggest **increased infection risk** and prolonged hospital stay - Early high-dose corticosteroids may increase risk of secondary infections (especially fungal) - The SCORTEN score (used to predict mortality) does NOT include corticosteroid use as a protective factor #### Current Consensus: - **Most major guidelines (including WHO and American Academy of Dermatology)** do NOT recommend routine systemic corticosteroids as first-line therapy - If used, they should be: - Started **very early** (within 24–48 hours) at **high doses** - Used for **short duration** (typically 3–5 days) - Combined with aggressive infection prevention - Reserved for cases with **rapidly progressive disease** or **extensive involvement** **High-Yield:** The evidence does NOT support systemic corticosteroids as a standard, evidence-based first-line treatment. They are **optional** and controversial, not universally appropriate. ### Alternative Immunosuppressants: Emerging Evidence **Cyclosporine (3–5 mg/kg/day):** - **High-Yield:** Emerging evidence suggests cyclosporine may be beneficial, especially in rapidly progressive SJS/TEN - Mechanism: Inhibits T cell activation and IL-2 production - Some retrospective studies show reduced mortality when combined with supportive care - May be preferred over systemic corticosteroids due to lower infection risk **Other agents with emerging evidence:** - **Intravenous immunoglobulin (IVIG):** Mixed results; some benefit in retrospective studies - **Tumor necrosis factor (TNF) inhibitors:** Limited data; experimental - **Plasmapheresis:** Anecdotal reports; not standard ### Management Algorithm ```mermaid flowchart TD A[Suspected SJS/TEN]:::outcome --> B[Stop causative drug immediately]:::action B --> C[Admit to ICU/Burn Unit]:::action C --> D[Aggressive Supportive Care]:::action D --> E{Rapidly progressive or extensive?}:::decision E -->|No| F[Supportive care alone]:::action E -->|Yes| G[Consider Cyclosporine or early high-dose corticosteroids]:::action F --> H[Monitor for infection, fluid balance, nutrition]:::action G --> H H --> I[Ophthalmology consult if mucosal involvement]:::action I --> J[Outcome: Healing or complications]:::outcome ``` ### Why Systemic Corticosteroids Are NOT "Appropriate" as Standard Therapy **Key Point:** While corticosteroids are sometimes used in clinical practice, they are **NOT universally recommended** or considered standard first-line therapy by major guidelines. The evidence base is weak and controversial. - No clear mortality benefit in meta-analyses - Increased infection risk if used improperly - Supportive care alone is the evidence-based foundation - Cyclosporine has emerging evidence as an alternative [cite:Harrison 21e Ch 56]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.